GY
GYRE.US Gyre Therapeutics Inc.
- Market cap
- USD 472M
- P/E
- -
- P/B
- 4.37x
- ROE
- -28.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GYRE.US undervalued?
Graham numberThe Graham number of Gyre Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Gyre Therapeutics Inc. fundamental analysis
No fundamental analysis for Gyre Therapeutics Inc. yet.
Gyre Therapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Gyre Therapeutics Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Pha…
Full company profileGyre Therapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Gyre Therapeutics Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 399K | 1.02M | 6.00K | - | 20.9M | 7.34M | 102M | 113M | 106M | 117M | 113M |
| Gross Profit | -10.2M | 845K | -143K | -146K | 11.8M | -332K | 97.5M | 109M | 102M | 111M | 106M |
| Operating Income | -20.4M | -21.8M | -33.8M | -57.3M | -57.4M | -83.7M | 9.20M | -67.2M | 16.2M | 11.5M | -33.7M |
| EBITDA | -20.0M | -21.6M | -33.8M | -55.0M | -56.1M | -87.6M | 10.5M | 20.3M | 17.8M | 16.9M | -31.0M |
| Net Income | -16.9M | -21.6M | -30.1M | -55.2M | -55.5M | -87.9M | 2.30M | -92.9M | 12.1M | 5.03M | -31.0M |
| EPS | -22 | -6.30 | -2.68 | -4.60 | -2.90 | -2.87 | 0.03 | -1.41 | 0.12 | 0.05 | -0.29 |
| Balance Sheet | |||||||||||
| Total Assets | 38.1M | 39.5M | 125M | 98.6M | 94.8M | 55.7M | 84.8M | 117M | 125M | 166M | 201M |
| Total Liabilities | 22.0M | 8.74M | 4.98M | 30.2M | 18.8M | 14.6M | 12.5M | 103M | 27.0M | 23.9M | 35.2M |
| Shareholders' Equity | 16.1M | 30.8M | 120M | 68.3M | 76.1M | 41.1M | 42.5M | -15.8M | 63.3M | 106M | 108M |
| Cash & Short-term Investments | 17.1M | 32.4M | 120M | 76.9M | 79.4M | 46.9M | 25.2M | 33.5M | 26.7M | 52.4M | 70.0M |
| Total Debt | 19.4M | 5.09M | - | 1.80M | 1.64M | 2.39M | 613K | 409K | 1.60M | 939K | 3.01M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -18.5M | -19.9M | -28.6M | -43.6M | -55.0M | -83.8M | 10.7M | 25.9M | -3.64M | 1.01M | -23.4M |
| Capital Expenditure | 468K | 23.0K | 376K | 64.0K | 267K | 839K | 5.00M | 8.59M | 3.13M | 1.19M | 3.26M |
| Free Cash Flow | -18.9M | -20.0M | -28.9M | -43.7M | -55.3M | -84.6M | 5.68M | 17.3M | -6.77M | -180K | -26.6M |
| Ratios | |||||||||||
| ROE | -105.4% | -70.1% | -25.1% | -80.7% | -73.0% | -214.0% | 5.4% | - | 19.1% | 4.7% | -28.7% |
| ROA | -44.5% | -54.6% | -24.1% | -56.0% | -58.6% | -158.0% | 2.7% | -79.7% | 9.6% | 3.0% | -15.4% |
| Net Profit Margin | -4,246.9% | -2,118.0% | -500,916.7% | - | -265.1% | -1,198.3% | 2.3% | -81.9% | 11.4% | 4.3% | -27.5% |
| Debt to Equity | 1.21x | 0.17x | - | 0.03x | 0.02x | 0.06x | 0.01x | - | 0.03x | 0.01x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Gyre Therapeutics Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | CNY 45.0M | 0.59 | 1,956.2% |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | CNY 3.95M | 1.15 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:15 on Oct 31, 2023.
Who owns Gyre Therapeutics Inc.
- Insiders 72.26%
- Institutions 8.88%
- Public & others 18.86%
- Shares outstanding 109M
- Free float 39.4M
Top funds holding GYRE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.04M | 0.97% | +69.64% | Sep 2026 |
| iShares Russell 2000 ETF | 386K | 0.36% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 200K | 0.19% | 0.00% | Aug 2026 |
| Schwab US Small-Cap ETF™ | 185K | 0.17% | +0.23% | Oct 2026 |
| Fidelity Extended Market Index | 166K | 0.16% | +50.81% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 101K | 0.09% | -0.38% | Oct 2026 |
| Fidelity Total Market Index | 95.6K | 0.09% | +155.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 90.6K | 0.08% | -14.32% | Sep 2026 |
| Fidelity Series Total Market Index | 63.1K | 0.06% | +97.35% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 62.2K | 0.06% | 0.00% | Aug 2026 |
| Multimanager Aggressive Equity IA | 43.2K | 0.04% | 0.00% | Sep 2026 |
| iShares Russell 2000 Value ETF | 41.7K | 0.04% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 38.5K | 0.04% | -14.29% | Sep 2026 |
| Bridge Builder Small Cap Fund | 28.5K | 0.03% | 0.00% | Oct 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 24.8K | 0.02% | -40.35% | Sep 2026 |
| Nuveen Small Cap Blend Idx R6 | 24.5K | 0.02% | 0.00% | Sep 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 22.7K | 0.02% | +203.92% | Jun 2026 |
Top institutions holding GYRE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HSG Holding Ltd | 3.75M | 3.50% | 0.00% | Jun 2026 |
| BlackRock Inc | 994K | 0.93% | +31.02% | Jun 2026 |
| Octagon Capital Advisors LP | 954K | 0.89% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 877K | 0.82% | -10.90% | Jun 2026 |
| Geode Capital Management, LLC | 533K | 0.50% | +23.54% | Jun 2026 |
| State Street Corp | 245K | 0.23% | +13.44% | Jun 2026 |
| Charles Schwab Investment Management Inc | 184K | 0.17% | +11.53% | Jun 2026 |
| Northern Trust Corp | 170K | 0.16% | +26.67% | Jun 2026 |
| SBI Securities Co Ltd | 167K | 0.16% | -2.39% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 151K | 0.14% | +9.73% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 124K | 0.12% | +77.55% | Jun 2026 |
| The Goldman Sachs Group Inc | 86.2K | 0.08% | +17.93% | Jun 2026 |
| Bank of New York Mellon Corp | 62.8K | 0.06% | +45.44% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 41.7K | 0.04% | +382.48% | Jun 2026 |
| STRS OHIO | 25.8K | 0.02% | +22.27% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 25.3K | 0.02% | 0.00% | Sep 2026 |
| AllianceBernstein L.P. | 24.6K | 0.02% | +12.64% | Jun 2026 |
| Nuveen, LLC | 24.5K | 0.02% | 0.00% | Jun 2026 |
| UBS Group AG | 18.8K | 0.02% | -11.02% | Jun 2026 |
| Rhumbline Advisers | 18.6K | 0.02% | +10.32% | Sep 2026 |
Gyre Therapeutics Inc. company profile
- Company name
- Gyre Therapeutics Inc.
- Ticker
- GYRE.US
- Exchange
- USA Stocks
- Listed since
- Apr 12, 2006
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 625
- Fiscal year end
- December
- Address
- 12730 High Bluff Drive, San Diego, CA, United States, 92130
- Phone
- 858-284-0115
- Website
- gyretx.com
About Gyre Therapeutics Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Gyre Therapeutics Inc. management
10- Mr. Thomas W. Eastling M.D.Chief Financial Officer · born 1959
- Mr. Weiguo YeChief Operating Officer · born 1978
- Ms. Ruoyu ChenChief Information Officer · born 1971
- Dr. Ying Luo Ph.D.CEO, President & Director · born 1965
- Dr. Yue Xiong Ph.D.Chief Scientific Officer & Director
- Mr. Joshua Bergmann J.D.General Counsel & Corporate Secretary
- Seth Goldblum M.B.A.Senior Vice President of Corporate Development
- Mr. Jialiang Wang Ph.D.Executive VP & GM
- Jing Liu Ph.D.Senior Vice President of Platform Chemistry
- Mark MarinoSenior Vice President of Clinical Development